Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Akiibinu, Moses O ^a,b   Ogundahunsi, Omobola A ^a   Ogunyemi, Ebenezer O ^a  

^a OLABISI ONABANJO UNIVERSITY   (Nigeria)

^b NONE   (Nigeria)

Author keywords

Oxidative stress; Schizophrenia; Thyroid hormones

Indexed keywords

BIOLOGICAL MARKER; MALONALDEHYDE; NITRIC OXIDE; PEROXIDE; THYROID HORMONE; THYROTROPIN;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; MALE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SCHIZOPHRENIA; THYROID GLAND;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; PEROXIDES; SCHIZOPHRENIA; THYROID GLAND; THYROID HORMONES; THYROTROPIN;

EID: 84859095622     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-169     Document Type: Article

References (45)

1. Fronto-temporal dysfunction in schizophrenia, a selective review. John JP, Indian J Psychiatr 2009 51 180 190 10.4103/0019-5545.55084
2. Working memory and long term memory deficits in schizophrenia; is there a common substrate? Van Snellenberg JX, Psychiatry Res 2009 174 89 96 10.1016/j.pscychresns.2009.04.001 19837568
3. Horrobin D, The lipid hypothesis of schizophrenic in brain lipids and disorders in biological psychiatry Amsterdam: Elsevier Science, Skinner ER, 2002 35 39 52
4. Epidemiology driven neuro-developmental animal models of schizophrenia. Meyer U, Feldon J, Prog Neurobiol 2009
5. Cannabis and psychosis; search of a causal link through a critical and systematic review. LeBee PY, Fatseas M, Denis C, Lavic E, Auriacombe M, Encéphale 2009 35 377 385
6. Schizophrenia. Van Os J, Kapur S, Lancet 2009 374 635 645 10.1016/S0140-6736(09)60995-8
7. Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE). I. Onset and distribution of disease-specific PrP accumulation in brain and viscera. Jeffrey M, Ryder SJ, Martin S, Hawkins SAC, Terry L, Berthelin-Baker C, Bellworthy SJ, J Comp Pathol 2001 124 280 289 10.1053/jcpa.2001.0465 (Pubitemid 32631563)
8. Dihydrochalcones from Piper longicaudatum. Joshi AS, Li XC, Nimrod AC, ElSohly HN, Walker LA, Clark AM, Planta Med 2001 67 186 188 10.1055/s-2001-11517 11301876 (Pubitemid 32234693)
9. Nitric oxide physiology, pathophysiology, and pharmacology. Moncada S, Palmer RMJ, Higgs EA, Pharmacol Rev 1991 43 109 142 1852778
10. The biology of nitrogen oxides in the airways. Gaston B, Drazen JM, Loscalzo J, Stanler JS, Am J Respir Crit Care Med 1994 149 538 551 7508323 (Pubitemid 24069009)
11. Inhibition of low-density lipoprotein oxidation by nitric oxide. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarthy S, FEBS Lett 1993 334 170 174 10.1016/0014-5793(93)81706-6 8224243 (Pubitemid 23330576)
12. Extensive nitration of protein tyrosine in human atheroscerosis detected by immunohistochemistry. Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR, Biol Chem Hoppe Seyler 1994 375 81 88 8192861
13. Cloning and characterization of the thyroid iodide transporter. Dai G, Levy O, Carrasco N, Nature 1996 379 458 460 10.1038/379458a0 8559252 (Pubitemid 26039527)
14. Characterization of ThOX proteins as components of the thyroid H2O2 -generating system. De Deken X, Wang D, Dumont JE, Miot F, Exp Cell Res 2002 273 187 196 10.1006/excr.2001.5444 11822874 (Pubitemid 34920669)
15. Peroxides and peroxide-degrading enzymes in the thyroid. Schweizer U, Chiu J, Kohrle J, Antioxid Redox Signal 2008 10 1577 1592 10.1089/ars.2008.2054 18498223 (Pubitemid 351931931)
16. Thyroid peroxidase and thyroxine biosynthesis. Taurog A, Recent Prog Horm Res 1970 26 189 247 4919091
17. Oxidative stress and neopterin abnormalities in Schizophrenia, A longitudinal study. Chittiprols VG, Neelakantachar N, Babu SV, Reddy NA, Shetty KT, Gangadhar BN, J Psychiatr Res 2009
18. Different neuro-endocrine profiles of remitted and non-remitted schizophrenic patients. Yazici K, Yazici AE, Taneli B, Prog Neuropsychopharmacol Biol Psychiatry 2002 26 579 584 10.1016/S0278-5846(01)00311-6 11999911 (Pubitemid 34252954)
19. Distinguishing between the validity and utility of psychiatric diagnoses. Kendell R, Jablensky A, Am J Psychiatry 2003 160 4 12 10.1176/appi.ajp.160.1.4 12505793 (Pubitemid 36042419)
20. Effects of drugs on clinical laboratory tests. Young DS, Pestaner LC, Gilberman U, Clin Chem 1975 21 3660
21. Effect of calmodulin antagonist on radiation-induced lipid peroxidation in microsomes. Varshney R, Kale RK, Int J Radiat Biol 1990 58 733 743 10.1080/09553009014552121 1977818 (Pubitemid 20346842)
22. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power (the FRAP assay). Benzie IE, Strain JJ, Anal Biochem 1996 239 70 76 10.1006/abio.1996.0292 8660627 (Pubitemid 26256285)
23. Increased oxidative stress in patients with hydatidiform mole. Harma M, Harma M, Enel O, Swiss Med Wkly 2003 133 563 566 14691728 (Pubitemid 37499328)
24. Pentoxiphylline Reduces Nitric Oxide Production among Patients with HIV Infection. Wanchu A, Khullar M, Bhatnagar A, Sud A, Bambery P, Singh S, Immunol Lett 2000 74 121 125 10.1016/S0165-2478(00)00241-8 10996387
25. Trauma and post traumatic stress disorder (PTSD) in patients with schizophrenia or schizoaffective disorder. Lommen MJ, Restifo K, Community Ment Health J 2009 S3 24
26. Psychotic disorders and Comorbidity somatic illness VS side effect. Kozumplik O, Uzum S, Jakovljevic M, Psychiatr Danub 2009 21 361 367 19794357
27. Experimental antipsycholtics and metabolic adverse effects-findings from clinical trials. Tschoner A, Flexishhacker FWW, Ebenbichler CF, Curr Opin Investig Drugs 2009 10 1041 1048 19777392
28. Evaluation of antioxidant deficit in schizophrenia. Dadheech G, Mishra S, Gautam S, Sharma P, Indian J Psychiatr 2008 50 16 20 10.4103/0019-5545.39753
29. Oxidative stress markers in bipolar disorder; A metanalysi. Andreazza AC, Kauer-Sant' Anna M, Frey BN, Bond DJ, Kapezinski F, Young LT, Yatham LN, J Affect Disord 2008 111 135 144 10.1016/j.jad.2008.04.013 18539338
30. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A, Prog Neuropsychopharmacol Biol Psychiatry 2009 33 1178 1183 10.1016/j.pnpbp.2009.06.018 19576938
31. Bioactive lipids in schizophrenia. Berger GE, Sinesny S, Amminger GP, Int Rev Psychiatry 2006 18 85 98 10.1080/09540260600583072 16777663 (Pubitemid 43791672)
32. status in schizophrenia. Suboticanec K, Vitamin C, Bibl Nutr Dieta 1986 38 173 181 3516139
33. Oxidative stress and ascorbic acid status in schizophrenics. Dadheech G, Mishra S, Gautam S, Sharma P, SFRR-Indian Bull 2005 4 23 25
34. Oxidative stress, -tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Dadheech G, Mishra S, Gautam S, Sharma P, Indian J Clin Biochem 2006 21 34 38 (Pubitemid 44756920)
35. The underlying mechanisms of brain allergies. Whitford T, J Orthomol Med 2000 15 5 14
36. Mono-oxygenation of N-acetylhistamine mediated by Lascorbate. Uchida K, Mitsui M, Kawakishi S, Biochim Biophys Acta 1989 991 377 379 10.1016/0304-4165(89)90131-1 2719978 (Pubitemid 19136745)
37. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. Straw GM, Bigelow LB, Kirch DG, J Clin Psychopharmacol 1989 9 130 132 10.1097/00004714-198904000- 00011 2566628 (Pubitemid 19098161)
38. The many faces of nitric oxide in schizophrenia. A Review. Bernstein H, Bogerts B, Keilhoff G, Schizophr Res 2005 78 69 86 10.1016/j.schres.2005.05.019 16005189 (Pubitemid 41188326)
39. Neuronal apoptosis in neurodegeneration. Okouchi M, Ekshyyan O, Maracine M, Aw TY, Antioxid Redox Signal 2007 9 1060 1096
40. Inhibition of low-density lipoprotein oxidation by nitric oxide. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarthy S, FEBS Lett 1993 334 170 174 10.1016/0014-5793(93)81706-6 8224243 (Pubitemid 23330576)
41. Extensive nitration of protein tyrosine in human atheroscerosis detected by immunohistochemistry. Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR, Biol Chem Hoppe Seyler 1994 375 81 88 8192861
42. Role of Nitric Oxide in Patients with Schizophrenia- a Systematic Review of the Literature. Oliveira JP, Zuardi AW, Hallak JE, Curr Psychiatr Rev 2008 4 219 227 10.2174/157340008786576553
43. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. Zoroglu SS, Herken H, Yürekli M, Uz E, Tutkun H, Sava HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, Akyol O, J Psychiatr Res 2002 36 309 315 10.1016/S0022-3956(02)00014-6 12127598 (Pubitemid 34764055)
44. Thyroid dysfunction in chronic schizophrenia within a state psychiatric hospital. Sim K, Chong SA, Chan YH, Lum NM, Ann Acad Med Singapore 2002 1 641 644
45. The hypothalamic-Pituitary-thyroid-axis in patients with schizophrenia. Baumgartner A, Pietzcker A, Gaebel W, Schizophr Res 2000 44 23 24